## Xiaozeng Wang

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8128410/publications.pdf

Version: 2024-02-01

933447 713466 34 452 10 21 citations h-index g-index papers 36 36 36 750 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Short-Term Rosuvastatin Therapy for Prevention of Contrast-Induced Acute Kidney Injury in Patients With Diabetes and Chronic Kidney Disease. Journal of the American College of Cardiology, 2014, 63, 62-70.	2.8	188
2	Magnetically Controlled Capsule Endoscopy for Assessment of Antiplatelet Therapy–Induced Gastrointestinal Injury. Journal of the American College of Cardiology, 2022, 79, 116-128.	2.8	37
3	A Randomized Trial Comparing the NeoVas Sirolimus-Eluting BioresorbableÂScaffold and MetallicÂEverolimus-Eluting Stents. JACC: Cardiovascular Interventions, 2018, 11, 260-272.	2.9	35
4	Biocompatibility and Effectiveness Evaluation of a New Hemostatic Embolization Agent: Thrombin Loaded Alginate Calcium Microsphere. BioMed Research International, 2017, 2017, 1-10.	1.9	20
5	Prognostic value of the age, creatinine, and ejection fraction score for nonâ€infarctâ€related chronic total occlusion revascularization after primary percutaneous intervention in acute STâ€elevation myocardial infarction patients: A retrospective study. Journal of Interventional Cardiology, 2018, 31, 33-40.	1.2	14
6	Predicting longâ€term ischemic events using routine clinical parameters in patients with coronary artery disease: The <scp>OPT</scp> â€ <scp>CAD</scp> risk score. Cardiovascular Therapeutics, 2018, 36, e12441.	2.5	14
7	Angiotensin-converting enzyme I/D polymorphism and the risk of thoracic aortic dissection in Chinese Han population. Molecular Biology Reports, 2013, 40, 1249-1254.	2.3	13
8	Safety and efficacy of the novel sirolimusâ€eluting bioresorbable scaffold for the treatment of de novo coronary artery disease: Oneâ€year results from a prospective patientâ€level pooled analysis of NeoVas trials. Catheterization and Cardiovascular Interventions, 2019, 93, 832-838.	1.7	12
9	Safety and efficacy of policosanol in patients with high onâ€treatment platelet reactivity after drugâ€eluting stent implantation: twoâ€year followâ€up results. Cardiovascular Therapeutics, 2016, 34, 337-342.	2.5	11
10	Firstâ€inâ€man study evaluating the safety and efficacy of a second generation biodegradable polymer sirolimusâ€eluting stent in the treatment of patients with de novo coronary lesions: Clinical, Angiographic, and <scp>OCT</scp> outcomes of <scp>CREDIT</scp> â€1. Catheterization and Cardiovascular Interventions, 2015, 85, 744-751.	1.7	10
11	Optimal antiplatelet therapy for prevention of gastrointestinal injury evaluated by ANKON magnetically controlled capsule endoscopy: Rationale and design of the OPT-PEACE trial. American Heart Journal, 2020, 228, 8-16.	2.7	10
12	Associations of urinary sodium and sodium to potassium ratio with hypertension prevalence and the risk of cardiovascular events in patients with prehypertension. Journal of Clinical Hypertension, 2017, 19, 1231-1239.	2.0	9
13	Rosuvastatin attenuated contrast-induced nephropathy in diabetes patients with renal dysfunction. International Journal of Clinical and Experimental Medicine, 2015, 8, 2342-9.	1.3	9
14	Efficacy and safety of oral Guanxinshutong capsules in patients with stable angina pectoris in China: a prospective, multicenter, double-blind, placebo-controlled, randomized clinical trial. BMC Complementary and Alternative Medicine, 2019, 19, 363.	3.7	8
15	Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double-blinded, placebo-controlled randomized trial. American Heart Journal. 2020, 228, 1-7.	2.7	7
16	Clinical efficacy and safety of biodegradable polymerâ€based sirolimusâ€eluting stents in patients with diabetes mellitus insight from the 4â€year results of the create study. Catheterization and Cardiovascular Interventions, 2013, 81, 1127-1133.	1.7	6
17	Impact of dual antiplatelet therapy duration on 1â€year clinical outcomes in diabetic patients with acute coronary syndrome undergoing percutaneous coronary intervention: Insights from the realâ€world OPTâ€CAD study. Catheterization and Cardiovascular Interventions, 2020, 95, 579-586.	1.7	6
18	Utility of S100A12 as an Early Biomarker in Patients With ST-Segment Elevation Myocardial Infarction. Frontiers in Cardiovascular Medicine, 2021, 8, 747511.	2.4	6

#	Article	IF	CITATIONS
19	Effects of intracoronary sodium nitroprusside compared with adenosine on fractional flow reserve measurement. Journal of Invasive Cardiology, 2014, 26, 119-22.	0.4	5
20	Emergency treatment of splenic injury in a novel mobile minimally invasive interventional shelter following disaster: a feasibility study. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine, 2014, 22, 44.	2.6	4
21	Impact of Diabetes Mellitus on Antithrombotic Management Patterns and Longâ€Term Clinical Outcomes in Patients With Acute Coronary Syndrome: Insights From the EPICOR Asia Study. Journal of the American Heart Association, 2020, 9, e013476.	3.7	4
22	Clinical Outcome between Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndrome and Diabetes. Cardiovascular Therapeutics, 2021, 2021, 1-9.	2.5	4
23	Percutaneous transluminal intervention and antiplatelet therapy following endovascular graft exclusion for Stanford B thoracic aortic dissection. International Journal of Cardiology, 2013, 165, 478-482.	1.7	3
24	Clinical significance of glycated hemoglobin in acute coronary syndrome patients from the CCC-ACS project. Herz, 2021, 46, 287-294.	1.1	3
25	Efficacy of clopidogrel and ticagrelor under NT-proBNP in hospitalized ST-elevation acute coronary syndrome patients on percutaneous coronary intervention: CCC-ACS Project Analysis. International Journal of Cardiology, 2020, 310, 1-8.	1.7	3
26	Suppression of lysosomal-associated protein transmembrane 5 ameliorates cardiac function and inflammatory response by inhibiting the nuclear factor-kappa B (NF-κB) pathway after myocardial infarction in mice. Experimental Animals, 2022, 71, 415-425.	1.1	3
27	A Novel Multiple Risk Score Model for Prediction of Long-Term Ischemic Risk in Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: Insights From the I-LOVE-IT 2 Trial. Frontiers in Cardiovascular Medicine, 2021, 8, 756379.	2.4	2
28	Age, estimated glomerular filtration rate and ejection fraction score predicts contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease: insight from the TRACK-D study. Chinese Medical Journal, 2014, 127, 2332-6.	2.3	2
29	Impact of extended dual antiplatelet therapy on longâ€term prognosis in patients with acute coronary syndrome complicated with anemia: A subâ€analysis of the realâ€world OPTâ€CAD study. Catheterization and Cardiovascular Interventions, 2021, 98, E235-E242.	1.7	1
30	Efficacy and safety of bivalirudin without post-procedure infusion in patients with coronary heart disease during elective percutaneous coronary intervention. Chinese Medical Journal, 2021, Publish Ahead of Print, .	2.3	1
31	Clinical feasibility and safety of a novel miniature mobile cardiac catheterization laboratory in diagnosis and treatment for coronary heart disease. Chinese Medical Journal, 2014, 127, 1052-6.	2.3	1
32	GW24-e1835â€Safety and long-term efficacy of left subclavian artery coverage during thoracic endovascular aortic repair. Heart, 2013, 99, A173.1-A173.	2.9	0
33	A mobile minimally invasive interventional shelter: a new answer to on-spot emergency treatment of large arterial injuries?. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine, 2015, 23, 63.	2.6	0
34	Long noncoding RNA PR11-387H17.6 as a potential novel diagnostic biomarker of atherosclerotic renal artery stenosis. Renal Failure, 2021, 43, 1188-1197.	2.1	O